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W. LENNEYWith the advent of widespread vaccination programmes,
the majority of viral infections which repeatedly plagued us
throughout the 20th century have been greatly reduced or
even abolished. However, the morbidity caused by the
respiratory syncytial virus (RSV) to the infant, his family
and the healthcare services remains virtually unchanged.
During the winter months (December to March in the
northern hemisphere) epidemics of RSV infections continue
to cause major problems in both primary and secondary
care, the virus being the leading cause of lower respiratory
tract infections in infants and young children (1). Passively
acquired maternal antibody, specific to RSV, declines in the
first few months of life but by 1 year of age up to 50% of all
babies will have been actively infected by RSV. This figure
rises to 90% by 3 years of age (2).
In the U.K. approximately 20 000 infants are admitted
each year with RSV-positive bronchiolitis, which is
approximately 3% of all U.K. yearly births. More than
50% of these admissions are between 1 and 3 months of
age, causing major stang and bed problems for all
paediatric units. Assuming the main pathophysiological
changes caused by the infection are centred around the
small airways with release of inflammatory mediators,
intense inflammation, oedema of the mucosa and the
production of copious secretions, it is not surprising that
pharmacological treatment has been disappointing.
Although there is still some dispute between clinicians in
different countries the consensus view is that in typical
infantile RSV-positive acute bronchiolitis there is little or
no place for bronchodilators (3) or steroids (4, 5). Some
studies using nebulized adrenaline (6, 7) have suggested
some improvement, whereas others (8) have not. Opinion
on the use of Ribavarin, a synthetic purine nucleotide
derivative, remains divided and large multi-centre, rando-
mized, controlled studies are still needed to assess the
benefits (9,10). A recent study (11) showed no benefit from
inhaled steroids in infants recovering from bronchiolitis.
The only agent which is agreed by all to be beneficial in
acute bronchiolitis is oxygen to maintain normal blood
oxygen saturation (SaO2) levels.
It is not only the acute episode of bronchiolitis which is
of concern. There are recognized long-term consequences
following RSV infection which have recently been exten-
sively reviewed (12). Approximately 50% of infants with
RSV lower respiratory tract infections will have recurrent
episodes of wheezing during early childhood. Pre-existing
lung function defects may also be related to long-term
airway morbidity. The recent study by Stein et al. (13),
following up a birth cohort for 13 years, was in agreement
with the long-term follow-up of babies hospitalized in
Nottingham due to acute bronchiolitis (14). Both studies0954-6111/01/030170+03 $35?00/0showed that after RSV bronchiolitis in infancy there is an
excess of respiratory symptoms for 11 and 10 years
respectively but with no excess of atopy in the RSV group.
Although atopy does not seem to play a major part in the
development of long-term morbidity following RSV infec-
tions, studies examining Th2 cytokine responses have given
conflicting results. One prospective study (15) has suggested
that RSV bronchiolitis during the first year of life is a risk
factor for the development of asthma and allergen
sensitization in the following 2 years, particularly in
children with a family history of atopy or asthma. Another
unanswered question is the relationship between the
development of chronic obstructive pulmonary disease
(COPD) in adult life and viral respiratory infections
(especially RSV) in infancy.
The burden of the short- and long-term repercussions of
RSV disease, in the light of ineffective pharmacotherapy, leads
us to look towards prevention as a possible way forward.
Active immunization using formalin-inactivated alum-com-
plexed vaccines has been disappointing. Four studies in sero-
negative children showed no decrease in acquisition of
infection but a greatly enhanced chance of severe lower
respiratory tract infection requiring hospital admission (21%
vs. 1?5%). The exaggerated response has been subsequently
reproduced in animal models. The main problem with an
RSV vaccine is the need to vaccinate in the first month of life
when passive maternal antibody levels are high and are
detrimental to the survival of a live attenuated virus.
Vaccination with a bovine RSV has been attempted in
animals but although protection was shown in rodents, the
same was not true when given to chimpanzees (16). Recent
viral research has attempted to produce mutant, less
virulent strains but to date none has been approved for
clinical use. Vectored antigens, subunit vaccines and DNA
vaccines have shown promise but are not at the stage of
testing in humans.
The only practical progress in prevention of RSV disease
since the discovery of the virus in the 1950s has been the
development of passive immunization initially using an
intravenous polyclonal antibody (17) and, more recently,
the humanized monoclonal antibody: palivizumab (18).
Palivizumab reacts with a conserved cross-protective
epitope on the F protein of RSV. It does not interfere with
other childhood immunizations. The key study regarding its
ecacy took place over the winter of 1996 in the U.S.A.,
U.K. and Canada (18). A total of 1502 high-risk infants
[those with bronchopulmonary dysplasia (BPD) or pre-
maturity of 35 weeks gestation or less] took part. Two-
thirds were given active prophylaxis, one-third received
placebo. Treatment consisted of five monthly intra-mus-
cular injections from November 1996 to March 1997. The# 2001 HARCOURT PUBLISHERS LTD
EDITORIAL 171primary outcome was hospitalization with RSV infection.
Palivizumab resulted in a 55% reduction in admissions for
RSV disease, fewer total RSV hospital days and fewer days
in hospital requiring O2. There were no differences between
active and placebo groups in the hospital admission rates
for non-RSV respiratory diseases, indicating pulivizumab’s
specificity for preventing RSV infections.
The conclusions of the impact-RSV study were that
monthly intra-muscular administration of palivizumab is
safe and effective for the prevention of serious RSV illness
in premature infants and those with BPD. Expanded access
studies in South Africa, South America and the northern
hemisphere (19) have confirmed the safety aspects of
palivizumab, and a ‘real life’ outcome study on its use in
the first year in the U.S.A. (1998–1999) (20) has confirmed
lower hospitalization rates in the same high-risk groups.
The rates were 2?1% for premature babies and 4% for
those with BPD (in the impact study they were 1?8% and
7?9%, respectively). It should be noted, however, that there
were no control infants in this study.
It is recognized that there are groups of infants at ‘high
risk’ of developing RSV lower respiratory tract infections:
pre-term infants, those with BPD, with cardiac disease or
with immune deficiencies. At present there is no informa-
tion on the ecacy of palivizumab in infants with cardiac
disease and as immune-deficient babies are at risk from
many viruses the polyclonal antibody respigam may be
preferred. The impact study included pre-term babies of 35
weeks gestation and below (under 6 months of age) and
BPD babies requiring treatment for BPD within the
previous 6 months (under 24 months of age). Given the
high cost of palivizumab (approximately £2000–£3500 per
baby for five injections) the question regarding which
babies should be considered for RSV prophylaxis remains.
We know that RSV infection is a major cause of
deterioration and re-hospitalization in young children with
BPD (21) and in those less than 32 weeks gestation (22).
Exact numbers of respiratory re-admissions in these high-
risk groups are not known but various studies indicate 10–
35% may be a reasonable range. The impact study
suggested the numbers of infants needed to be treated
(NNT) to prevent one hospital admission was 17. However,
in the placebo arm only 10?6% were admitted. It may be
that in ‘real life’ the NNT may be considerably less.
It seems unlikely that, given the present cost of
palivizumab, it will be possible to show true cost-effective-
ness in European countries and it must be remembered that
the majority of infants admitted to hospital with RSV
bronchiolitis are not in a ‘high risk’ group. Beyond this,
however, are other issues which have rarely been addressed.
These involve quality of life, the views of parents and the
ethics of withholding a treatment that has been shown to be
effective and safe. Babies who have already received weeks
of neonatal intensive care because of extreme prematur-
ity+BPD have already cost the Health Services huge
amounts of money to keep them alive and in comparison
the cost of a course of five palivizumab injections is
relatively low. The decision to offer palivizumab is clearly
complex and this is shown in the varied responses
throughout the U.K. at present. The decision should notrest on cost-effectiveness alone but needs to be considered
in the light of the total quality of care we offer to our
patients. With this in mind the American Academy of
Pediatrics issued guidelines for the use of RSV prophylaxis
in 1998 (23) and more recently in the U.K. (September
2000) the Midland Therapeutic Review and Advisory
Committee (MTRAC) (24) recommended: ‘the decision to
use palivizumab should be made by a specialist. It is then
appropriate for general practitioners to prescribe and
administer the course of intra-muscular injections. Within
the region, paediatric units are further restricting the use of
palivizumab, within its licensed indications for the children
at greatest risk of complications due to RSV’. In reality this
means those babies with severe BPD, especially those
discharged home still requiring O2 therapy and very pre-
term babies discharged from the neonatal unit shortly
before or during the RSV season.
RSV disease remains a major burden to those infants at
risk, their families and the healthcare services. Active
management of RSV bronchiolitis has changed little over
the last 30 years. Passive immunization is now available and
recommended for use in those at highest risk. The decision
to use it lies with specialists. This decision is complex and
extends beyond the bounds of cost-effectiveness. It seems
unlikely that further advances will be available to clinicians
in the management of RSV disease for some considerable
time.
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